NLS Pharma Group, of Stans, Switzerland, started enrollment for a phase II experiment to determine the efficacy, safety, tolerability and pharmacokinetics of a controlled release formulation of mazindol in adults with DSM-5 attention deficit hyperactivity disorder (ADHD).